Podcast Summary: The Neuro Experience

Episode: What Men Over 40 Need to Know About Prostate Care

Host: Louisa Nicola
Guest: Dr. Shawn Zimberg
Release Date: December 16, 2025

Overview

This episode dives deep into the essential knowledge men over 40 need for optimal prostate care. Louisa Nicola interviews Dr. Shawn Zimberg, a leading board-certified radiation oncologist, about prostate health, cancer risk, screening, diagnostic advances, treatment options, and practical advice for patients. The discussion dispels myths, clarifies emerging science, and offers nuanced, actionable guidance for men seeking to take charge of their health.

Key Discussion Points and Insights

1. The Silent Prevalence and Complexity of Prostate Cancer

• Many men have prostate cancer without symptoms.
  • "Thousands of men lose their sexual function every year, treating a cancer that was never going to kill them." (A, 00:00)
  • Cadaver studies show many men who died of unrelated causes harbored prostate cancer cells undetected in life. Lifetime risk is about 1 in 7 or 8 men. (B, 02:11; 11:28)
  • Not all prostate cancers are aggressive or life-threatening: "When we use the term prostate cancer, it's really not the best term... it's a wide, wide spectrum of diseases that behave very differently." (B, 11:28)

2. Understanding Prostate Anatomy & Function

• The prostate is a gland that produces seminal fluid, "shaped like a walnut," and is heavily influenced by male hormones, especially testosterone. (B, 02:11; 03:39)
• Enlargement (BPH) is common and unrelated to cancer risk, but can affect urination. (B, 02:11)
• Prostate size does not predict cancer risk ("You can have a man with a massive, benign, enlarged prostate and another man with a small prostate harboring aggressive cancer." (A, 04:43))

3. PSA Testing — Value, Limitations, & Controversies

• PSA is a valuable but imperfect screening tool.
  • Elevated PSA can be from benign conditions, not just cancer. (B, 06:29; 15:32)
  • "A high PSA just by itself doesn't mean that somebody has prostate cancer... you really have to look at other factors." (B, 15:32)
  • Trends and PSA density provide better context; annual testing helps see the trajectory. (B, 19:19)
• Age Recommendations: Start at 50 (or earlier with family risk); debate over cutoff at age 70. (A, 17:27; B, 17:27)
  • "If a simple blood test can be taken in an 80 year old and find an aggressive prostate cancer... I find it a little bit of pretzel logic that you would suggest... not to do it." (B, 17:27)

4. Genetic and Modifiable Risk Factors

• Family history increases risk significantly, but not as deterministically as other diseases like Alzheimer's.
  • "If it's a parent or uncle...typically a man should start getting their PSA maybe 5 to 10 years younger than their father or uncle was diagnosed." (B, 19:28)
• Genetic and molecular testing are transforming risk assessment by revealing tumor aggressiveness beyond what Gleason scores show. (B, 13:30; 28:00)

5. Screening Beyond PSA: MRI & Biopsy Techniques

• Multi-parametric MRI is now standard to detect suspicious prostate lesions and guide biopsies.
• MRI-fusion biopsies allow targeted sampling of abnormal areas, increasing accuracy.
• Shift from transrectal (higher infection risk) to transperineal biopsies for safety and precision. (B, 28:58)
  • "The risk of sepsis is virtually eliminated" with transperineal approach. (B, 28:58)

6. Decoding the Gleason Score

• Determines aggressiveness by examining cancer cell patterns; ranges from least to most aggressive (6 to 10).
• A “7” can mean very different risks (3+4 vs. 4+3), affecting treatment choices. (B, 35:39)
  • "The 3 is the least aggressive... the 5 is the most aggressive. The predominant pattern is the first number." (B, 33:21)

7. Treatment Pathways: Surveillance, Surgery, Radiation

• Three primary options after diagnosis:
  1. Active Surveillance: For low-risk, low-volume cancers.
     • "If the entire picture looks like the train hasn't left the station yet... we can continue to monitor you." (B, 39:45)
     • Rigorous follow-up is essential; doesn't compromise cure rates if progression is caught early.
  2. Surgery (Radical Prostatectomy): Now almost always robotic, aiming to spare erectile nerves when possible.
     • "The robot was the first real procedure that was indicated for robot-assisted use." (B, 47:01)
  3. Radiation: Focal therapy—now involving advanced mapping, image guidance, and protective measures (e.g., rectal spacers).
     • "If we can move the tissues away from the high doses of radiation... you're going to leave the patient with less risk of complications." (B, 65:45)

8. Innovations: Rectal Spacer Balloon (Bioprotect)

• Dr. Zimberg is a leader in deploying a biodegradable balloon that protects the rectum during radiation, improving cure rates and preserving function.
  • "It's always going to be symmetric...solves a lot of problems that we see with the gels." (B, 62:38)
  • "I've done almost 2,000 of these... Putting in a rectal spacer, I believe is standard of care." (B, 65:36; 65:45)

9. Metastatic Prostate Cancer & Radioligand Therapy

• Stage 4 commonly spreads to bone.
• New PSMA-targeted radioligand therapy delivers radiation directly to metastatic cells, improving survival.
  • "It can attach to the prostate cancer... delivers radiation right to the DNA of that cancer and destroys the cancer. Men who get that therapy live longer..." (B, 43:38)

10. Testosterone & Prostate Cancer

• "Testosterone doesn't cause prostate cancer, but men who have prostate cancer, the testosterone can almost fuel the prostate cancer..." (B, 48:46)
• Androgen suppression is used to weaken aggressive cancers before/during radiation.
• Exogenous testosterone (TRT) does not show a clear correlation with prostate cancer in healthy men, but replacement therapy is avoided in prostate cancer survivors for several years. (B, 51:36)

11. Debunking Ejaculation & Prostate Cancer Myths

• "That study has a positive trend... There are other studies which do not show that... meta-analysis... does not appear that number of times that a man ejaculates... is related to prostate cancer." (B, 25:39)
• Frequent ejaculation may help clear fluids, but does not have a proven cancer-preventing effect.

12. Prostatitis and Cancer Risk

• Chronic prostatitis can raise PSA, but definitive correlation with cancer is unclear; repeat testing after antibiotics is standard practice. (B, 27:19)

13. Radiation Basics

• Targets DNA in cancer cells, overwhelming their repair mechanisms.
• Normal tissue is more resilient; the challenge is minimizing collateral dose. (B, 53:01)

14. Lifestyle Factors and Prevention

• Family history and age dominate risk; no lifestyle intervention has definitive protective effect.
  • "Unfortunately like all cancers, there's so much we know and there's so much we don't know... get your PSAs." (B, 66:44)

Notable Quotes & Memorable Moments

• On over-treatment:
  “Thousands of men lose their sexual function every year, treating a cancer that was never going to kill them.” (A, 00:00)

• On lifetime risk:
  “The lifetime risk of men in general is one out of seven. One out of eight men.” (B, 02:24, 11:28)

• On PSA screening cutoffs:
  “I find it a little bit of pretzel logic that you would suggest… not to do it.” (B, 17:27)

• On molecular testing:
  "It's almost like looking under the hood of a car... under the hood, it could be completely different." (B, 13:30)

• On the balloon spacer:
  “That balloon... is biodegradable... and it dissolves after three months.” (B, 63:35)

• On the “train leaving the station”:
  “If the entire picture looks like the train hasn't left the station yet... we can continue to monitor you.” (B, 39:45)

• On testosterone and treatment:
  “Testosterone doesn’t cause prostate cancer, but men who have prostate cancer, the testosterone can almost fuel the prostate cancer.” (B, 48:46)

Timestamps: Important Segments

• Understanding prostate cancer’s spectrum: 00:05; 11:28
• PSA testing and its nuances: 06:29; 15:32; 19:19
• MRI and biopsy advances: 20:44; 28:58
• Explaining Gleason scores: 31:12; 35:18
• Choosing treatments (surveillance, surgery, radiation): 39:27; 47:01
• Metastatic disease & radioligand therapy: 43:38
• Role of testosterone: 48:46; 51:36
• Rectal balloon innovation: 55:42; 62:38
• Myths about ejaculation: 25:39
• Lifestyle factors: 66:44

Final Advice

Dr. Zimberg’s Key Message:
"Get your PSAs... if we had something like the PSA for all cancers, we would be much, much closer to curing cancer globally. So the PSA is really a remarkable test."

For Listeners Seeking Quick Takeaways:

• Screening saves lives – PSA is imperfect but valuable; context and trends are more important than one-off values.
• Treatment should be individualized, using modern imaging, molecular diagnostics, and tailored therapies.
• Don’t ignore early symptoms or family history – start checks earlier if risk is elevated.
• Innovations continue to improve outcomes and reduce side effects – stay informed and seek multidisciplinary advice.
• Lifestyle: No guaranteed preventive measure, but regular monitoring and healthy habits are encouraged.
• Testosterone therapy in healthy men is not clearly linked to cancer risk, but avoid in cancer survivors.

For more information, see the show notes or contact Dr. Zimberg’s clinic in New York.

End of summary.